Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has provided an update.
Consun Pharmaceutical Group Ltd. has announced the successful dosing of the first cohort in a Phase 1 clinical trial for their SK-08 Tablet, a Category 1 innovative drug targeting chronic kidney disease (CKD). The SK-08 Tablet, developed with a unique mechanism of action, aims to address the global health challenge posed by CKD by improving kidney function and reducing proteinuria. This development marks a significant milestone for the company, potentially filling a gap in CKD treatment options and reinforcing its commitment to innovative therapeutics.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Ltd. is a company operating in the pharmaceutical industry, focusing on the development of innovative drugs. The company is involved in creating treatments for chronic kidney disease and holds global intellectual property rights for its products.
YTD Price Performance: -15.05%
Average Trading Volume: 2,534
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €787.3M
For detailed information about 1681 stock, go to TipRanks’ Stock Analysis page.